Up to 50% of patients with metastatic human epidermal growth factor receptor 2 amplified (HER2+) breast cancer develop brain metastases and have a median survival of 18–36 months, despite multimodal therapy including surgery, radiation, and HER2-directed therapies1,2. This evidence concerns the gene ERBB2 and breast carcinoma.